Onconetix (NASDAQ:ONCO) Major Shareholder Financial Lp Hrt Buys 74,350 Shares of Stock

Onconetix, Inc. (NASDAQ:ONCO) major shareholder Financial Lp Hrt bought 74,350 shares of the business’s stock in a transaction dated Tuesday, April 14th. The stock was purchased at an average price of $0.77 per share, with a total value of $57,249.50. Following the purchase, the insider directly owned 104,498 shares of the company’s stock, valued at $80,463.46. The trade was a 246.62% increase in their position. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. Large shareholders that own 10% or more of a company’s shares are required to disclose their transactions with the SEC.

Financial Lp Hrt also recently made the following trade(s):

• On Wednesday, April 15th, Financial Lp Hrt bought 92,554 shares of Onconetix stock. The stock was acquired at an average cost of $0.76 per share, for a total transaction of $70,341.04.

Onconetix Price Performance

NASDAQ ONCO opened at $0.76 on Friday. The firm has a market cap of $498,560.00, a PE ratio of 0.00 and a beta of 3.63. Onconetix, Inc. has a one year low of $0.67 and a one year high of $74.29. The stock’s 50 day simple moving average is $2.96 and its 200 day simple moving average is $8.92.

Institutional Trading of Onconetix

An institutional investor recently bought a new position in Onconetix stock. Pacific Capital Wealth Advisors Inc. bought a new stake in Onconetix, Inc. (NASDAQ:ONCO) in the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm bought 13,000 shares of the company’s stock, valued at approximately $40,000. Pacific Capital Wealth Advisors Inc. owned approximately 0.84% of Onconetix as of its most recent filing with the Securities and Exchange Commission (SEC). Institutional investors and hedge funds own 23.89% of the company’s stock.

About Onconetix

Onconetix, Inc, a biotechnology company, focuses on the research, development, and commercialization of solutions for men's health and oncology. It offers Entadfi, an FDA-approved, once daily pill that combines finasteride and tadalafil for the treatment of benign prostatic hyperplasia; and Proclarix, an in vitro protein-based blood diagnostic test for prostate cancer. The company was formerly known as Blue Water Biotech, Inc and changed its name to Onconetix, Inc in December 2023. Onconetix, Inc was incorporated in 2018 and is headquartered in Cincinnati, Ohio.